TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 213 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 3.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,838,000 | +175.0% | 37,718 | -1.8% | 0.01% | +333.3% |
| Q1 2022 | $1,032,000 | -44.0% | 38,426 | -0.5% | 0.00% | -40.0% |
| Q4 2021 | $1,842,000 | -30.5% | 38,615 | -3.2% | 0.01% | -16.7% |
| Q3 2021 | $2,649,000 | -45.4% | 39,881 | -35.9% | 0.01% | -45.5% |
| Q2 2021 | $4,852,000 | -19.5% | 62,186 | -2.4% | 0.01% | -31.2% |
| Q1 2021 | $6,026,000 | -23.4% | 63,706 | -1.4% | 0.02% | -20.0% |
| Q4 2020 | $7,869,000 | -2.5% | 64,581 | -30.1% | 0.02% | -13.0% |
| Q3 2020 | $8,068,000 | +59.0% | 92,358 | +17.5% | 0.02% | +35.3% |
| Q2 2020 | $5,075,000 | +7.0% | 78,570 | -26.0% | 0.02% | +70.0% |
| Q1 2020 | $4,744,000 | +26.6% | 106,224 | +76.6% | 0.01% | -28.6% |
| Q4 2019 | $3,746,000 | +99.3% | 60,138 | +20.3% | 0.01% | +100.0% |
| Q3 2019 | $1,880,000 | +15.5% | 50,000 | +25.0% | 0.01% | +16.7% |
| Q2 2019 | $1,628,000 | – | 40,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,392,297 | $291,501,000 | 6.94% |
| Burrage Capital Management LLC | 72,484 | $8,832,000 | 6.73% |
| MPM BioImpact LLC | 617,372 | $75,226,000 | 6.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 113,541 | $13,816,000 | 3.77% |
| Orbimed Advisors | 2,745,327 | $334,518,000 | 2.93% |
| SECTORAL ASSET MANAGEMENT INC | 257,379 | $31,362,000 | 2.21% |
| Parkman Healthcare Partners LLC | 59,377 | $7,235,000 | 1.85% |
| Nicholas Investment Partners, LP | 183,676 | $22,381,000 | 1.73% |
| EMERALD ADVISERS, LLC | 357,038 | $43,505,000 | 1.44% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 336,173 | $40,963,000 | 1.42% |